The study evaluated substrate cleavage product(s) generated by three botulinum neurotoxin serotype A (BoNT/A) medicinal drug products utilizing a novel and highly specific, light-chain activity, high-performance liquid chromatography (LCA-HPLC) method. Samples were reacted with a commercially available BoNT/A fluorescent substrate derived from the SNAP-25 sequence. Reaction products were separated by reversed-phase HPLC. The method detected an atypical cleavage pattern by one of the formulated drug products. IncobotulinumtoxinA produced two cleavage fragments rather than the single fragment typically generated by BoNT/A. Identification confirmed the secondary cleavage at a position corresponding to SNAP-25 Arg198–Ala199 (normal BoNT/A cleavage is Gln197–Arg198). Arg198–Ala199 is also the cleavage site for trypsin and serotype C toxin. Normal cleavage was observed for all other BoNT/A drug product samples, as well as 900-kD and 150-kD bulk toxin BoNT/A. The reason for this unexpected secondary cleavage pattern by one formulated BoNT/A drug product is unknown. Possible explanations include a contaminating protease and/or damage to the 150-kD type-A toxin causing nonspecific substrate recognition and subsequent cleavage uncharacteristic of type-A toxin. The BoNT/A drug products were also analyzed via the LCA-HPLC assay using a commercial BoNT/C fluorescent substrate derived from the syntaxin sequence. Cleavage of the serotype C substrate by incobotulinumtoxinA was also confirmed whilst neither of the other drug products cleaved the syntaxin substrate.
References
[1]
Oguma, K.; Fujinaga, Y.; Inoue, K. Structure and Function of Clostridium botulinum Toxins. Microbiol. Immunol.？1995, 39, 161–168. 7603360
[2]
Vaidyanathan, V.V.; Yoshino, K.; Jahnz, M.; Dorries, C.; Bade, S.; Nauenburg, S.; Niemann, H.; Binz, T. Proteolysis of SNAP-25 Isoforms by Botulinum Neurotoxin Types A, C, and E: Domains and Amino Acid Residues Controlling the Formation of Enzyme-Substrate Complexes and Cleavage. J. Neurochem.？1999, 72, 327–337. 9886085
[3]
Jones, R.G.A.; Liu, Y.; Sesardic, D. New Highly Specific Botulinum Type C1 Endopeptidase Immunoassays Utilising SNAP25 or Syntaxin Substrates. J. Immunol. Methods？2009, 343, 21–27, doi:10.1016/j.jim.2009.01.001. 19176217
[4]
Schmidt, J.J.; Stafford, R.G.; Millard, C.B. High-Throughput Assays for Botulinum Neurotoxin Proteolytic Activity: Serotypes A, B, D, and F. Anal. Biochem.？2001, 296, 130–137, doi:10.1006/abio.2001.5236. 11520041
[5]
Rasooly, R.; Do, P.M. Development of an in Vitro Activity Assay as an Alternative to the Mouse Bioassay for Clostridium botulinum Neurotoxin Type A. Appl. Environ. Microbiol.？2008, 74, 4309–4313, doi:10.1128/AEM.00617-08. 18515481
[6]
Hunt, T.; Clarke, K. Potency of the botulinum toxin product CNBTX-A significantly exceeds labelled units in standard potency test. J. Am. Acad. Dermatol.？2008, 58, 517–518, doi:10.1016/j.jaad.2007.11.015. 18280358
[7]
Shimizu, G.; Rupp, D.; Tam, K.; Aoki, K.R.; Hunt, T. Characterization of Time-Dependent Enzymatic Profiles Under Various Liquid Conditions for 150 and 900 kDa Botulinum Type-A Neurotoxins. Toxicon？2008, 51 (suppl.), 21.
[8]
Shine, N.R.; Crawford, K.R.; Eaton, L.J.A. Substrate Peptides and Assays for Detecting and Measuring Proteolytic Activity of Serotype A Neurotoxin From Clostridium botulinum. U.S. Patent 6,504,006, 7 January 2003.
[9]
Humeau, Y.; Doussau, F.; Grant, N.; Poulain, B. How Botulinum and Tetanus Neurotoxins Block Neurotransmitter Release. Biochimie？2000, 82, 427–446, doi:10.1016/S0300-9084(00)00216-9. 10865130
[10]
Hunt, T.; Clarke, K. Potency evaluation of a Formulated Drug Product Containing 150-kD Botulinum Neurotoxin Type A. Clin. Neuropharmacol.？2009, 32 (1), 28–31. 18978494
